# Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment

> **NCT01140607** · PHASE1 · COMPLETED · sponsor: **Sanofi** · enrollment: 56 (actual)

## Conditions studied

- Neoplasm Malignant

## Interventions

- **DRUG:** Cabazitaxel (XRP6258)

## Key facts

- **NCT ID:** NCT01140607
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2014-07
- **Final completion:** 2014-07
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2015-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01140607

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01140607, "Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01140607. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*